Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 6/20 | 0.50 |
| ▸ | RAB9A | P51151 | 6/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.50 |
| ▸ | PPARA | Q07869 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 4/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.49 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.49 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.49 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.48 |
| ▸ | PGR | P06401 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20333771 | 0.84 | NPC1 (0.56) | NPC1RAB9ASMN1; SMN2MAPTMEN1 | |
| SCHEMBL20347415 | 0.83 | PTPN1 (0.46) | NPC1RAB9ASMN1; SMN2MAPTMEN1 | |
| SCHEMBL22216489 | 0.83 | MAPT (0.57) | NPC1RAB9ASMN1; SMN2MAPTMEN1 | |
| SCHEMBL22216671 | 0.83 | MEN1 (0.60) | NPC1RAB9ASMN1; SMN2MAPTMEN1 | |
| SCHEMBL13152874 | 0.82 | NPC1 (0.60) | NPC1RAB9ASMN1; SMN2MAPTMEN1 | |
| SCHEMBL19961863 | 0.81 | SMN1; SMN2 (0.48) | SMN1; SMN2PPARAPTPN1ALDH1A1 | |
| SCHEMBL20333766 | 0.79 | RAB9A (0.50) | NPC1RAB9ASMN1; SMN2MAPTMEN1 | |
| SCHEMBL21602301 | 0.79 | LMNA (0.44) | NPC1SMN1; SMN2MAPTGAAALDH1A1 | |
| SCHEMBL20350671 | 0.77 | ALDH1A1 (0.47) | NPC1RAB9ASMN1; SMN2MAPTMEN1 | |
| SCHEMBL20347162 | 0.77 | HPGD (0.50) | NPC1RAB9ASMN1; SMN2KDM4EPTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230002437-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | ANTENGENE THERAPEUTICS LIMITED (CN) | 2023-01-05 | — | — | US | disclosed |
| US-11034715-B2 | Ectonucleotidase inhibitors and methods of use thereof | CALITHERA BIOSCIENCES, INC. (US) | 2021-06-15 | — | — | US | disclosed |
| US-20200223882-A1 | Ectonucleotidase Inhibitors and Methods of Use Thereof | ANTENGENE THERAPEUTICS LIMITED (CN) | 2020-07-16 | — | — | US | disclosed |
| US-10570167-B2 | Ectonucleotidase inhibitors and methods of use thereof | CALITHERA BIOSCIENCES, INC. (US) | 2020-02-25 | — | — | US | disclosed |
| US-20180186827-A1 | Ectonucleotidase Inhibitors and Methods of Use Thereof | ANTENGENE THERAPEUTICS LIMITED (CN) | 2018-07-05 | — | — | US | disclosed |
| US-20180186827-A1 | Ectonucleotidase Inhibitors and Methods of Use Thereof | ANTENGENE THERAPEUTICS LIMITED (CN) | 2018-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180186827-A1 | Ectonucleotidase Inhibitors and Methods of Use Thereof | NT5E, ENTPD5, NT5C2 | NPC1 885/4885RAB9A 3127/4885SMN1; SMN2 3679/4885 |
| US-20200223882-A1 | Ectonucleotidase Inhibitors and Methods of Use Thereof | NT5E, ENTPD5, NT5C2 | NPC1 885/4885RAB9A 3127/4885SMN1; SMN2 3679/4885 |
| US-11034715-B2 | Ectonucleotidase inhibitors and methods of use thereof | NT5E, ENTPD5, NT5C2 | NPC1 885/4885RAB9A 3127/4885SMN1; SMN2 3679/4885 |
| US-10570167-B2 | Ectonucleotidase inhibitors and methods of use thereof | NT5E, ENTPD5, NT5C2 | NPC1 885/4885RAB9A 3127/4885SMN1; SMN2 3679/4885 |
| US-20230002437-A1 | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | NT5E, ENTPD5, NT5C2 | NPC1 885/4885RAB9A 3127/4885SMN1; SMN2 3679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.